We initiate Medios with BUY rating and a EUR 65 price target as we believe Medios can go on to consolidate its market leading position in the specialty pharmaceutical sector in Germany. With a strong track record of growth and excellent relations with rest of the industry we believe Medios can stand to capitalise on the fast-growing specialty pharma market. We see significant upside in the share price in the light of recent acquisitions Medios’ has executed in the past 18 months with positive lo...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.